INTENSITY THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
INTENSITY THERAPEUTICS, INC. (INTS) reported Increase (Decrease) in Accrued Liabilities of -$1.37 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-11-13
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was -$1.12M, a 409.25% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $362.69K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month |
|---|---|---|---|
| 2023-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.37M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$246.77K 10-Q · filed 2023-08-14 | ||
| 2022-09-30 | $362.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $986.19K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $623.50K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |